Publications by authors named "Ronald Doll"

Claim this Profile
P
Phe19 modification of HDM2-p53 PPI inhibitors to alleviate CYP3A4 metabolism/mechanism-based inhibition liability.
Yuan Tian, Brian R Lahue, Yao Ma, Latha G Nair, Weidong Pan, Ronald J Doll

Bioorg Med Chem Lett· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.
Sobhana Babu Boga, Yongqi Deng, Liang Zhu, Yang Nan, Alan B Cooper, Ronald Doll

ACS Med Chem Lett· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.
Sobhana Babu Boga, Abdul-Basit Alhassan, Alan B Cooper, Ronald Doll, Neng-Yang Shih

Bioorg Med Chem Lett· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a highly potent orally bioavailable imidazo-[1, 2-a]pyrazine Aurora inhibitor.
Tao Yu, Yonglian Zhang, Angela D Kerekes, Jayaram R Tagat, Ronald J Doll

Bioorg Med Chem Lett· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors.
Stéphane L Bogen, Weidong Pan, Craig R Gibeau, Brian R Lahue, Yao Ma, Ronald J Doll

ACS Med Chem Lett· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.
Weidong Pan, Brian R Lahue, Yao Ma, Latha G Nair, Gerald W Shipps, Ronald Doll

Bioorg Med Chem Lett· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioisosteric approach to the discovery of imidazo[1,2-a]pyrazines as potent Aurora kinase inhibitors.
Zhaoyang Meng, Bheemashankar A Kulkarni, Angela D Kerekes, Amit K Mandal, Sara J Esposite, Ronald J Doll

Bioorg Med Chem Lett· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aurora kinase inhibitors based on the imidazo[1,2-a]pyrazine core: fluorine and deuterium incorporation improve oral absorption and exposure.
Angela D Kerekes, Sara J Esposite, Ronald J Doll, Jayaram R Tagat, Tao Yu

J Med Chem· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.
David Parry, Timothy Guzi, Frances Shanahan, Nicole Davis, Deepa Prabhavalkar, Ronald Doll

Mol Cancer Ther· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.
Kamil Paruch, Michael P Dwyer, Carmen Alvarez, Courtney Brown, Tin-Yau Chan, Ronald J Doll

ACS Med Chem Lett· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core.
Tao Yu, Jayaram R Tagat, Angela D Kerekes, Ronald J Doll, Yonglian Zhang

ACS Med Chem Lett· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53.
Mark Demma, Eugene Maxwell, Robert Ramos, Lianzhu Liang, Cheng Li, Ronald Doll

J Biol Chem· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards the second generation of Boceprevir: Dithianes as an alternative P2 substituent for 2,2-dimethyl cycloproyl proline in HCV NS3 protease inhibitors.
Latha G Nair, Stephane Bogen, Sumei Ruan, Weidong Pan, Russel Pike, Ronald J Doll

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
Stéphane L Bogen, Ashok Arasappan, Francisco Velazquez, Melissa Blackman, Regina Huelgas, Ronald Doll

Bioorg Med Chem· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of C-imidazole azaheptapyridine FPT inhibitors.
Hugh Y Zhu, Alan B Cooper, Jagdish Desai, George Njoroge, Paul Kirschmeier, Ronald J Doll

Bioorg Med Chem Lett· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mass spectrometric studies of potent inhibitors of farnesyl protein transferase--detection of pentameric noncovalent complexes.
Urooj A Mirza, Guodong Chen, Yan-Hui Liu, Ronald J Doll, Viyyoor M Girijavallabhan

J Mass Spectrom· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-guided discovery of cyclin-dependent kinase inhibitors.
Thierry O Fischmann, Alan Hruza, José S Duca, Lata Ramanathan, Todd Mayhood, Ronald J Doll

Biopolymers· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors.
Michael P Dwyer, Kamil Paruch, Carmen Alvarez, Ronald J Doll, Kerry Keertikar

Bioorg Med Chem Lett· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazolo[1,5-a]pyrimidines as orally available inhibitors of cyclin-dependent kinase 2.
Kamil Paruch, Michael P Dwyer, Carmen Alvarez, Courtney Brown, Tin-Yau Chan, Ronald J Doll

Bioorg Med Chem Lett· November 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of cyclin-dependent kinases - a review of the recent patent literature.
Andrea D Basso, Ronald J Doll

Recent Pat Anticancer Drug Discov· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guiding farnesyltransferase inhibitors from an ECLiPS library to the catalytic zinc.
Chia-Yu Huang, Tara M Stauffer, Corey L Strickland, John C Reader, He Huang, Ronald J Doll

Bioorg Med Chem Lett· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of the ERK1,2 transcriptome in mammary epithelial cells.
Constance Grill, Ferdous Gheyas, Priya Dayananth, Weihong Jin, Wei Ding, Ronald J Doll

Biochem J· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intra-S-phase checkpoint activation by direct CDK2 inhibition.
Yonghong Zhu, Carmen Alvarez, Ronald Doll, Hirokazu Kurata, Xiao Min Schebye

Mol Cell Biol· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Farnesyltransferase inhibitors as anticancer agents: critical crossroads.
Ronald J Doll, Paul Kirschmeier, W Robert Bishop

Curr Opin Drug Discov Devel· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of fluoxetine, pemoline and placebo on heart period and QT variability in normal humans.
Robert Pohl, Richard Balon, Anusha Jayaraman, Ronald G Doll, Vikram Yeragani

J Psychosom Res· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis